How long should we allow metformin to remain the bogeyman in CKD? Should MALA scare us from ever letting our patients benefit from metformin? Join us as we discuss some rare prospective data on metformin in moderate to severe CKD.
news
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies,
Background, news
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
Background, news
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
Background
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
